BFM
XENE icon

Boothbay Fund Management’s Xenon Pharmaceuticals XENE Stock Holding History

Boothbay Fund Management’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-35,700
Closed -$1.6M – 2523
2025
Q4 		$1.6M Buy
+35,700
New +$1.5M 0.02% 650
2021
Q4 		– Sell
-22,900
Closed -$350K – 2269
2021
Q3 		$350K Buy
+22,900
New +$398K 0.01% 1255

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Boothbay Fund Management's XENE Position: Q2 2026 in Review

Boothbay Fund Management reduced its Xenon Pharmaceuticals (XENE) stake by 32% in Q2 2026, selling an estimated $4.83M and leaving 183,343 shares worth $11.1M. The position accounts for 0.15% of the portfolio, ranked #138.

Boothbay Fund Management first reported a position in XENE in Q2 2018 and has held it in 30 quarters since. The position peaked at $15.7M in Q1 2026. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • Boothbay Fund Management held 183,343 shares of Xenon Pharmaceuticals worth $11.1M as of Q2 2026.
  • Boothbay Fund Management sold 87,069 Xenon Pharmaceuticals shares in Q2 2026, an estimated $4.83M.
  • Xenon Pharmaceuticals made up 0.15% of Boothbay Fund Management's portfolio in Q2 2026, its #138 holding.
  • Boothbay Fund Management first reported a position in Xenon Pharmaceuticals in Q2 2018 and has held it in 30 quarters since.
  • Boothbay Fund Management's Xenon Pharmaceuticals position peaked at $15.7M in Q1 2026.
  • 315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.